C. Nardo

发表

Descriptive epidemiology of blood pressure response to change in body position. The ARIC study.

L. Chambless, A. Sharrett, W. Rosamond, 1999, Hypertension.

Orthostatic hypotension and the incidence of coronary heart disease: the Atherosclerosis Risk in Communities study.

A. Sharrett, M. Szklo, W. Rosamond, 2000, American journal of hypertension.

Non-insulin-dependent diabetes mellitus and fasting glucose and insulin concentrations are associated with arterial stiffness indexes. The ARIC Study. Atherosclerosis Risk in Communities Study.

V. Salomaa, A. Folsom, W. Riley, 1995, Circulation.

Non-insulin-dependent diabetes mellitus and fasting glucose and insulin concentrations are associated with arterial stiffness indexes. The ARIC Study. Atherosclerosis Risk in Communities Study.

Veikko Salomaa, V. Salomaa, A. Folsom, 1995, Circulation.

T cell receptor peptide vaccination in rheumatoid arthritis : A placebo-controlled trial using a combination of Vβ3, Vβ14, and Vβ17 peptides

T. C. Adamson, V. Strand, D. Carlo, 1998 .

Vaccination with a CDR2 BV6S2/6S5 peptide in adjuvant induces peptide-specific T-cell responses in patients with multiple sclerosis.

R. Moss, D. Carlo, C. Nardo, 2001, Journal of neuroscience research.

T cell receptor peptide vaccination in rheumatoid arthritis: a placebo-controlled trial using a combination of Vbeta3, Vbeta14, and Vbeta17 peptides.

T. C. Adamson, V. Strand, D. Carlo, 1998, Arthritis and rheumatism.

Results of a Phase II Rheumatoid Arthritis Clinical Trial Using T-Cell Receptor Peptides

T. C. Adamson, V. Strand, D. Carlo, 1999 .

OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial.

C. Nardo, P. Radziszewski, C. Chapple, 2013, European urology.

OnabotulinumtoxinA for the treatment of patients with overactive bladder and urinary incontinence: results of a phase 3, randomized, placebo controlled trial.

Xiaohong Yan, R. Dmochowski, C. Nardo, 2013, The Journal of urology.

OnabotulinumtoxinA 100U provides significant improvements in overactive bladder symptoms in patients with urinary incontinence regardless of the number of anticholinergic therapies used or reason for inadequate management of overactive bladder

C. Nardo, V. Nitti, S. Herschorn, 2014, International journal of clinical practice.

Long-Term Survival after Complete Surgical Resection and Adjuvant Immunotherapy for Distant Melanoma Metastases

Jeffrey E. Lee, R. Elashoff, D. Morton, 2017, Annals of Surgical Oncology.

1367 ONABOTULINUMTOXINA IN PATIENTS WITH OVERACTIVE BLADDER AND URINARY INCONTINENCE: CONSISTENT EFFECT OVER REPEAT TREATMENT

C. Nardo, V. Nitti, C. Chapple, 2013 .

Predictors of HIV‐specific lymphocyte proliferative immune responses induced by therapeutic vaccination

R. Moss, M. Wallace, R. Steigbigel, 2002, Clinical and experimental immunology.

OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial.

C. Nardo, P. Radziszewski, C. Chapple, 2013, European urology.